Eisai Co., Ltd. announced that it has signed a license agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate, an in-house developed selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in China, Hong Kong, Macau and Taiwan. Eisai will retain the rights to tasulgratinib worldwide outside the license territory, and will continue to manufacture and sell the drug in Japan, where it has already been launched.
Under this agreement, the Company will receive an upfront payment, as well as development and regulatory milestone payments, and, once launched, sales milestone payments and certain royalties based on sales revenue.
こちらもお読みください： カーディナル・ヘルス株式会社が最新の経腸栄養ポンプを発売
Taslugratinib is a novel orally administered tyrosine kinase inhibitor that exhibits selective inhibitory activity against FGFR1, FGFR2, and FGFR3. In Japan, the drug has been approved for the treatment of “FGFR2 fusion gene-positive, unresectable biliary tract cancer that has progressed after chemotherapy,” and has been on the market since November 2024. In addition, a Phase I clinical trial for estrogen receptor-positive, HER2-negative breast cancer patients is currently underway in Japan.
SciClone is a global biopharmaceutical company with an integrated platform for the development and commercialization of treatments for cancer and serious infectious diseases, and has a strong presence in Greater China. Through this license agreement, we hope to maximize the value of this agent in the licensed territory and contribute to patients in need as soon as possible.
ソース ACNN NewsWire
